Immunocore (NASDAQ:IMCR) Given New $100.00 Price Target at HC Wainwright

Immunocore (NASDAQ:IMCR) had its target price upped by HC Wainwright from $90.00 to $100.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 67.08% from the stock’s current price.

A number of other brokerages have also recently commented on IMCR. SVB Leerink assumed coverage on Immunocore in a research note on Monday, April 29th. They issued an “outperform” rating and a $74.00 price target for the company. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price target (up previously from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. Canaccord Genuity Group lifted their price objective on Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research note on Thursday, February 29th. Guggenheim restated a “buy” rating and set a $92.00 price target on shares of Immunocore in a report on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.00.

Immunocore Trading Down 2.4 %

NASDAQ:IMCR traded down $1.47 during trading hours on Thursday, hitting $59.85. The stock had a trading volume of 540,493 shares, compared to its average volume of 475,137. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -51.46 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.77 and a current ratio of 3.80. The business’s 50 day moving average is $60.76 and its 200-day moving average is $61.33. Immunocore has a one year low of $42.21 and a one year high of $76.98.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The company had revenue of $70.30 million for the quarter, compared to the consensus estimate of $70.72 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.35) earnings per share. Sell-side analysts anticipate that Immunocore will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunocore

Several institutional investors have recently bought and sold shares of the stock. Orion Portfolio Solutions LLC grew its position in Immunocore by 33.7% in the 1st quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company’s stock worth $1,503,000 after purchasing an additional 5,826 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Immunocore by 86.3% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock valued at $22,230,000 after acquiring an additional 158,455 shares during the last quarter. FORA Capital LLC bought a new stake in Immunocore during the first quarter worth $777,000. Capstone Investment Advisors LLC bought a new stake in Immunocore during the first quarter worth $1,227,000. Finally, Principal Financial Group Inc. boosted its position in Immunocore by 7.0% in the first quarter. Principal Financial Group Inc. now owns 517,204 shares of the company’s stock worth $33,618,000 after purchasing an additional 33,868 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.